Compounds for the treatment of canine Leishmaniosis

Patent number:

P202230181

No items found.

New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American trypanosomiasis or Chagas disease. Pharmacokinetic and toxicity studies have been conducted in rats, as well as preliminary efficacy studies in a murine model.

Countries:

Spain

Regions:

Community of Madrid

Centers:

CSIC

Other entities:

Sectors:

Food & Agro

Subsectors:

Pharmaceuticals

TRL Level:

TRL 4 – technology validated in lab

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

Los compuestos desarrollados han demostrado 100% de eficacia in vitro sobre parásitos causantes de leishmaniosis. El índice terapéutico (in vitro) hacía estos parásitos es alto (> 76 contra Leishmania, > 69 contra T. cruzi). Se han obtenido datos prometedores en ensayos de eficacia in vivo en modelo murino de Leishmaniosis visceral mediante administración oral del compuesto líder.

Comments

Other related patents

Food & Agro

Environment & Water

Other

Computer implemented method for generating an image of a surface

Countries

Spain

Food & Agro

Sensor device and associated method for the collection and processing of kinematic data from a terrestrial animal

Countries

Spain

Food & Agro

USE OF VOLATILE ORGANIC COMPOUNDS OF PARASITIC FUNGI OF INVERTEBRATES AS REPELLENTS OF THE BLACK BANANA WEEVIL (COSMOPOLITES SORDIDUS)

Countries

Spain

Get back to patents directory